Pflug Koory LLC lessened its position in shares of Stryker Co. (NYSE:SYK) by 15.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 900 shares of the medical technology company’s stock after selling 166 shares during the period. Pflug Koory LLC’s holdings in Stryker were worth $185,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of the company. BlackRock Inc. increased its position in Stryker by 0.6% during the 1st quarter. BlackRock Inc. now owns 25,036,303 shares of the medical technology company’s stock worth $4,945,168,000 after purchasing an additional 153,391 shares in the last quarter. FMR LLC increased its position in Stryker by 13.4% during the 1st quarter. FMR LLC now owns 6,728,182 shares of the medical technology company’s stock worth $1,328,951,000 after purchasing an additional 793,560 shares in the last quarter. Fundsmith LLP increased its position in Stryker by 1.0% during the 1st quarter. Fundsmith LLP now owns 5,581,841 shares of the medical technology company’s stock worth $1,102,525,000 after purchasing an additional 52,688 shares in the last quarter. Northern Trust Corp increased its position in Stryker by 1.2% during the 1st quarter. Northern Trust Corp now owns 3,903,582 shares of the medical technology company’s stock worth $771,036,000 after purchasing an additional 46,183 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Stryker by 6.5% during the 4th quarter. Geode Capital Management LLC now owns 3,665,205 shares of the medical technology company’s stock worth $573,387,000 after purchasing an additional 224,785 shares in the last quarter. 73.48% of the stock is owned by institutional investors.
NYSE SYK traded up $1.46 on Friday, hitting $216.76. The company’s stock had a trading volume of 16,179 shares, compared to its average volume of 1,092,561. The company has a quick ratio of 1.26, a current ratio of 2.07 and a debt-to-equity ratio of 0.67. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $222.59. The company’s 50-day moving average is $210.48 and its 200 day moving average is $194.87. The firm has a market cap of $81.97 billion, a PE ratio of 29.65, a PEG ratio of 2.66 and a beta of 0.85.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend is Friday, September 27th. Stryker’s dividend payout ratio (DPR) is currently 28.45%.
In other news, CFO Glenn S. Boehnlein sold 2,700 shares of the company’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $214.16, for a total value of $578,232.00. Following the sale, the chief financial officer now directly owns 20,633 shares of the company’s stock, valued at approximately $4,418,763.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Timothy J. Scannell sold 4,666 shares of the company’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $197.68, for a total transaction of $922,374.88. Following the completion of the sale, the insider now directly owns 155,347 shares in the company, valued at $30,708,994.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,431 shares of company stock valued at $3,174,489. Corporate insiders own 7.20% of the company’s stock.
A number of equities analysts recently issued reports on SYK shares. BTIG Research reiterated a “buy” rating and set a $228.00 price objective on shares of Stryker in a research report on Monday, July 29th. Morgan Stanley upped their price objective on shares of Stryker from $218.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 16th. Svb Leerink reiterated an “outperform” rating on shares of Stryker in a research report on Wednesday, July 10th. Oppenheimer upped their price objective on shares of Stryker from $183.00 to $192.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Finally, Canaccord Genuity upped their price objective on shares of Stryker from $195.00 to $233.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Five analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Stryker has an average rating of “Buy” and an average price target of $214.89.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: Ex-Dividend
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.